These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 37939122)
1. Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors. Orozco JJ; Vo PT; Gooley TA; Haaf RL; Lundberg SJ; Hamlin DK; Wilbur DS; Matesan MC; Fisher DR; Gopal AK; Green DJ; Pagel JM; Sandmaier BM Clin Cancer Res; 2024 Jan; 30(2):274-282. PubMed ID: 37939122 [TBL] [Abstract][Full Text] [Related]
2. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648 [TBL] [Abstract][Full Text] [Related]
3. Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. Mawad R; Gooley TA; Rajendran JG; Fisher DR; Gopal AK; Shields AT; Sandmaier BM; Sorror ML; Deeg HJ; Storb R; Green DJ; Maloney DG; Appelbaum FR; Press OW; Pagel JM Biol Blood Marrow Transplant; 2014 Sep; 20(9):1363-8. PubMed ID: 24858425 [TBL] [Abstract][Full Text] [Related]
4. Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from Australia and New Zealand Transplant and Cellular Therapies. Abadir E; Othman J; Kwan J; Gottlieb DJ; Kennedy GA; Bajel A; Doocey R; Perera T; Watson AM; Bardy PG; Greenwood M; Curtis DJ; Tran S; Moore J; Hamad N Transplant Cell Ther; 2024 Mar; 30(3):334.e1-334.e7. PubMed ID: 38029962 [TBL] [Abstract][Full Text] [Related]
5. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421 [TBL] [Abstract][Full Text] [Related]
6. Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Vydra J; Válková V; Čemusová B; Kolář M; Nováková L; Soukup P; Šálek C; Vraná M; Pytlík R; Lesný P; Vítek A; Cetkovský P; Marková M Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):365-371. PubMed ID: 30905537 [TBL] [Abstract][Full Text] [Related]
7. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174 [TBL] [Abstract][Full Text] [Related]
8. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses. Cruijsen M; Hobo W; van der Velden WJFM; Bremmers MEJ; Woestenenk R; Bär B; Falkenburg JHF; Kester M; Schaap NPM; Jansen J; Blijlevens NNM; Dolstra H; Huls G Biol Blood Marrow Transplant; 2016 Jun; 22(6):1000-1008. PubMed ID: 26860635 [TBL] [Abstract][Full Text] [Related]
9. Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI. Redondo S; García-Cadenas I; Vila A; Esquirol A; Portos JM; Novelli S; Saavedra S; Moreno C; Garrido A; Arguello-Tomas M; Oñate G; López-Pardo J; Caballero AC; Miqueleiz S; Briones J; Sierra J; Sancho G; Martino R Eur J Haematol; 2023 Jul; 111(1):146-153. PubMed ID: 37058419 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Rashidi A; Hamadani M; Zhang MJ; Wang HL; Abdel-Azim H; Aljurf M; Assal A; Bajel A; Bashey A; Battiwalla M; Beitinjaneh AM; Bejanyan N; Bhatt VR; Bolaños-Meade J; Byrne M; Cahn JY; Cairo M; Ciurea S; Copelan E; Cutler C; Daly A; Diaz MA; Farhadfar N; Gale RP; Ganguly S; Grunwald MR; Hahn T; Hashmi S; Hildebrandt GC; Holland HK; Hossain N; Kanakry CG; Kharfan-Dabaja MA; Khera N; Koc Y; Lazarus HM; Lee JW; Maertens J; Martino R; McGuirk J; Munker R; Murthy HS; Nakamura R; Nathan S; Nishihori T; Palmisiano N; Patel S; Pidala J; Olin R; Olsson RF; Oran B; Ringden O; Rizzieri D; Rowe J; Savoie ML; Schultz KR; Seo S; Shaffer BC; Singh A; Solh M; Stockerl-Goldstein K; Verdonck LF; Wagner J; Waller EK; De Lima M; Sandmaier BM; Litzow M; Weisdorf D; Romee R; Saber W Blood Adv; 2019 Jun; 3(12):1826-1836. PubMed ID: 31201170 [TBL] [Abstract][Full Text] [Related]
11. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome. Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418 [TBL] [Abstract][Full Text] [Related]
12. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation. Truscott L; Pariury H; Hanmod S; Davini M; de la Maza M; Sapp LN; Staples K; Proytcheva M; Katsanis E Pediatr Blood Cancer; 2023 Feb; 70(2):e30102. PubMed ID: 36394072 [TBL] [Abstract][Full Text] [Related]
13. Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Giebel S; Labopin M; Schroeder T; Swoboda R; Maertens J; Bourhis JH; Grillo G; Salmenniemi U; Hilgendorf I; Kröger N; Poiré X; Cornelissen JJ; Arat M; Savani B; Spyridonidis A; Nagler A; Mohty M Am J Hematol; 2023 Apr; 98(4):580-587. PubMed ID: 36626592 [TBL] [Abstract][Full Text] [Related]
14. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Bush SA; Hui TE; Martin PJ; Mitchell D; Press OW Blood; 1995 Feb; 85(4):1122-31. PubMed ID: 7849300 [TBL] [Abstract][Full Text] [Related]
15. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Marcoux C; Marin D; Ramdial J; AlAtrash G; Alousi AM; Oran B; Kebriaei P; Popat UR; Rezvani K; Champlin RE; Shpall EJ; Mehta RS Am J Hematol; 2023 May; 98(5):712-719. PubMed ID: 36734029 [TBL] [Abstract][Full Text] [Related]
16. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903 [TBL] [Abstract][Full Text] [Related]
17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation. Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158 [TBL] [Abstract][Full Text] [Related]
19. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618 [TBL] [Abstract][Full Text] [Related]
20. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies. Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]